The genetics industry provides data that life science companies need to make new products. Here’s a look at the largest genetics stocks.
From diagnostics to drug development, the genetics industry provides information that biotechnology, pharmaceutical and medical device companies need to develop innovative products. The largest genetics stocks are responsible for these advances.
That’s why we’re counting down some significant players in genetics and genomics — companies that splice and edit their days away, developing technologies and tests that are key for the life science sector.
The following US-listed companies specialize in different areas and work on a range of products in the field of genetics. Without further ado, here are the five largest genetics stocks to watch. This largest genetics stocks list was compiled using TradingView’s stock screener on May 12, 2022.
1. Amgen (NASDAQ:AMGN)
Market cap: US$130.73 billion
A global leader in biotechnology, Amgen uses advanced human genetics to develop and manufacture therapeutics targeting a variety of diseases with unmet medical needs.
Amgen states on its website that no other company has made a bigger bet on using human genetics to drive research and development. The firm is committed to aggressively leveraging human genetics in its research. Its aim is to move from one-off discoveries and instead take an industrial-scale approach to gene-based research.
For 2022, the company has set its total revenue guidance at US$25.4 billion to US$26.5 billion.
2. Regeneron Pharmaceuticals (NASDAQ:REGN)
Market cap: US$69.64 billion
Regeneron Pharmaceuticals is engaged in developing, manufacturing and commercializing medicines for cancer, pain and a wide variety of diseases including but not limited to inflammatory, cardiovascular, metabolic, hematologic and rare diseases. Regeneron’s product portfolio includes nine US Food and Drug Administration (FDA) approved treatments and numerous product candidates in development. The biotech company’s Regeneron Genetics Center is conducting one of the world’s largest genetics sequencing efforts.
Regeneron recently acquired Checkmate Pharmaceuticals (NASDAQ:CMPI), a clinical stage biotechnology company whose main product candidate, vidutolimod (CMP-001), is an advanced generation biologic designed to trigger the human body's immune system to attack tumors in combination with other therapies.
3. Vertex Pharmaceuticals (NASDAQ:VRTX)
Market cap: US$61.6 billion
Global biotech company Vertex Pharmaceuticals develops and commercializes therapies for treating cystic fibrosis. The firm’s product portfolio includes multiple approved treatments for patients with cystic fibrosis, and it has a pipeline of genetic and cell therapies for diseases such as sickle cell disease, beta thalassemia, Duchenne muscular dystrophy and type 1 diabetes.
Vertex has a partnership with Obsidian Therapeutics to develop up to five new gene-editing therapies, and a partnership with CRISPR Therapeutics (NASDAQ:CRSP) to develop potential new treatments targeting the underlying genetic causes of human disease using CRISPR’s gene editing technology.
4. BioNTech (NASDAQ:BNTX)
Market cap: US$38.4 billion
Immunotherapy company BioNTech has won global recognition for its therapeutic drug platforms, which allow for the rapid development of novel biopharmaceuticals targeting cancer and other serious diseases. The company’s oncology product candidate pipeline includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules.
In addition to its diverse oncology pipeline, BioNTech and its collaborators are leveraging the company’s expertise in mRNA vaccine development and in-house manufacturing capabilities to develop multiple mRNA vaccine candidates for a range of infectious diseases. Pfizer’s (NYSE:PFE) COVID-19 vaccine was created in partnership with BioNTech and is based on BioNTech’s proprietary mRNA technology. In April 2022, the company announced positive results from a Phase 2/3 clinical trial of a booster dose of the vaccine in healthy children 5 through 11 years of age.
5. Illumina (NASDAQ:ILMN)
Market cap: US$34.16 billion
Illumina develops, manufactures and markets life science tools and integrated systems that enable the implementation of genomic solutions for the healthcare sector. The company’s customers are mainly in the research, clinical and applied markets.
In May 2022, Illumina announced a five-year partnership with investment firm Deerfield Management aimed at researching the genetic causes of disease and developing new therapies using genomics and artificial intelligence. Illumina also recently established a partnership in the field of precision medicine with Johnson & Johnson’s (NYSE:JNJ) Janssen division.
This is an updated version of an article originally published by the Investing News Network in 2016.
Don’t forget to follow us @INN_LifeScience for real-time news updates!
Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.